Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
Novo Nordisk (Present Leader - Semaglutide Portfolio) CagriSema Mechanism: GLP-1 + Amylin agonist Stage: Phase 3 Expected filing: 2026 Weight loss: ~22-23% in trials Amycretin Mechanism: GLP-1 + Amylin Route: injectable + oral research Stage: Phase 2 Next-gen Oral GLP-1 programs Partnership with biotech firms to develop new oral obesity drugs 2
Breanne Kallonen to unravel the multifaceted causes of female hair loss
Eligible patients were evaluated by a PCP for medication optimization at routine scheduled appointments (Fig
Net margins contract to around 15% due to lower volumes and pricing pressure, causing EPS to flatten or fall to $1.6 or less
US$ 23.75
US$ 22.18
,aspect=ignore)
,aspect=ignore)
,aspect=ignore)
US$ 25.93
US$ 26.73
US$ 24.59
US$ 27.51
